KRAS and neoplasm: An elegant study demonstrated that [25] anti-estrogen fulvestrant and pan-HER inhibitor (dacomitinib) reduced the oncogenic interplay between ER and RTKs (EGFR) to exert synergistic anti-tumor effects in mouse models of KRAS mutant lung cancer.